Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150, February 2012

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors

  • Arlene Chan

      Affiliations

    • Mount Medical Centre, 41, 146 Mounts Bay Rd, Perth, Western Australia 6000, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 618 94814522; fax: +61 618 94814544.
    • ,
  • Shailendra Verma

      Affiliations

    • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    • ,
  • Sibylle Loibl

      Affiliations

    • German Breast Group, Neu-Isenburg, Germany
    • ,
  • Jeffrey Crawford

      Affiliations

    • Duke University Medical Center, Durham, NC, USA
    • ,
  • Mi Rim Choi

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Lyndah Dreiling

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Ted Vandenberg

      Affiliations

    • University of Western Ontario, London, ON, Canada

Accepted 11 March 2011. published online 20 April 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1040-8428(11)00070-9

doi:10.1016/j.critrevonc.2011.03.003

Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150, February 2012

Article Tools

* Image Usage & Resolution